Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: A prospective study

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Li, Si Wei ^a,b,c   Wang, Hua ^b   Liu, Mei Lian ^a   Zhang, Hai Bo ^b   Xiang, Yan Qun ^b   Lv, Xing ^b   Xia, Wei Xiong ^b   Zeng, Mu Sheng ^b   Mai, Hai Qiang ^b   Hong, Ming Huang ^b   Guo, Xiang ^b  

^a GUILIN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c Tumor Hospital of Yichang City   (China)

Author keywords

Chemoradiotherapy; Metastasis; Nasopharyngeal carcinoma; Prognosis; Prospective study; RKIP

Indexed keywords

CISPLATIN; FLUOROURACIL; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84871137903     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0322-9     Document Type: Article

References (33)

1. Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13:163-71.
2. Mai HQ, Zeng ZY, Zhang CQ, et al. Elevated plasma big ET-1 is associated with distant failure in patients with advanced-stage nasopharyngeal carcinoma. Cancer. 2006;106:1548-53.
3. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27:242-9.
4. Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys. 2008;71:1356-64.
5. Han L, Lin SJ, Pan JJ, et al. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Chin J Cancer. 2010;29:145-50.
6. Chua DT, Nicholls JM, Sham JS, Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:11-20.
7. Al-Mulla F, Bitar MS, Taqi Z, et al. RAF kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility. Mol BioSyst. 2011;7:928-41.
8. Fu Z, Smith PC, Zhang L, et al. Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst. 2003;95:878-89.
9. Hagan S, Al-Mulla F, Mallon E, et al. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res. 2005;11:7392-7.
10. Li HZ, Gao Y, Zhao XL, et al. Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol Cancer Res. 2009;7:832-40.
11. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res. 2004;64:5186-92.
12. Li HZ, Wang Y, Gao Y, et al. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol Cancer Res. 2008;6:917-28.
13. Chen Y, Ouyang GL, Yi H, et al. Identification of RKIP as an invasion suppressor protein in nasopharyngeal carcinoma by proteomic analysis. J Proteome Res. 2008;7:5254-62.
14. Chen Y, Tang CE, Ouyang GL, et al. Identification of RKIP as a differentially tyrosine-phosphorylated protein in nasopharyngeal carcinoma and normal nasopharyngeal epithelial tissues by phosphoproteomic approach. Med Oncol. 2009;26:463-70.
15. Al-Mulla F, Bitar MS, Al-Maghrebi M, et al. Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3β. Cancer Res. 2011;71:1334-43.
16. Al-Mulla F, Bitar MS, Feng J,et al. A new model for raf kinase inhibitory protein induced chemotherapeutic resistance. PLoS One. 2012;7(1):e29532. Epub 2012 Jan 18.
17. Wu K, Bonavida B. The activated NF-kappa B-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol. 2009;29:241-54.
18. Vega MI, Martínez-Paniagua M, Huerta-Yepez S, González- Bonilla C, Uematsu N, Bonavida B. Dysregulation of the cell survival/anti- apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization. Int J Oncol. 2009;35:1289-96.
19. Baritaki S, Yeung K, Palladino M, Berenson J. Bonavida B Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Res. 2009;69:8376-85.
20. Baritaki S, Bonavida B. Viral infection and cancer: the NF-kappaB/Snail/RKIP loop regulates target cell sensitivity to apoptosis by cytotoxic lymphocytes. Crit Rev Immunol. 2010;30:31-46.
21. Chatterjee D, Bai Y, Wang Z, et al. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem. 2004;279:17515-23.
22. Woods Ignatoski KM, Grewal NK, Markwart SM, et al. Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:153-60.
23. Ouyang GL, Chen Y, Yi H, et al. Effects of RKIP on the proliferation of nasopharyngeal carcinoma cells. [Article in Chinese]. Int J Pathol Clin Med. 2008;28:0001-5.
24. Ruan L, Wang GL, Yi H, et al. Raf kinase inhibitor protein correlates with sensitivity of nasopharyngeal carcinoma to radiotherapy. J Cell Biochem. 2010;110:975-84.
25. Chen Y, Li J, Yi H, et al. Low RKIP expression correlation with invasion, metastasis, and the activation of NF-κB signal transduction pathway in NPC. [Article in Chinese]. Prog Biochem Biophys. 2009;36:880-9.
26. Zlobec I, Minoo P, Baumhoer D, et al. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer. 2008;112:495-502.
27. Al-Mulla F, Hagan S, Behbehani AI, et al. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol. 2006;24:5672-9.
28. Minoo P, Zlobec I, Baker K, et al. Loss of Raf-1 kinase inhibitor protein (RKIP) expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol. 2007;127:820-7.
29. Liu SJ, Sun YM, Tian DF, et al. Down regulated NM23-H1 expression is associated with intracranial invasion of nasopharyngeal carcinoma. Br J Cancer. 2008;98:363-9.
30. Jiang WZ, Liao YP, Zhao SP, Wu HJ. Expression clinical significance of nm23-H1 and vessel endothelium growth factor protein in nasopharyngeal carcinoma. [Article in Chinese]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2006;41:200-4.
31. Li G, Wu Z, Peng Y, et al. MicroRNA-10b induced by Epstein-Barr virus-encoded latent membrane protein-1 promotes the metastasis of human nasopharyngeal carcinoma cells. Cancer Lett. 2010;299:29-36.
32. Pasqualetti G, Ricciardi S, Mey V, Del Tacca M, Danesi R. Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines. Lung Cancer. 2011;74:197-205.
33. Ricciardi S, Mey V, Nannizzi S, et al. Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells. Chemotherapy. 2010;56:303-12.